KLF2 and familial pancreatic carcinoma: This study provides the first direct evidence that DUXAP8 is a critical and powerful regulator of genes involved in pancreatic cancer progression through silencing CDKN1A and KLF2 in the nucleus, indicating that DUXAP8 is a potential therapeutic target of pancreatic cancer.